The US Food and Drug Administration is changing its requirements for late-stage clinical trials. The aim is to make sure that the diversity of people enrolled in these kinds of trials match up with those who will be using them. A report on cancer therapeutics between 2012 and 2017 found that 79% of these clinical trials adequately represented women. What's still an issue is things like minority, racial and ethnic groups not being adequately represented or excluded entirely.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode